Bioscience

Cancer Center studies lead to new trials for malignant melanoma treatment

July 18, 2009

By Flinn Foundation

[Source: Sara Hammond, Arizona Cancer Center] – Research at the Arizona Cancer Center has resulted in the opening of a Phase 3 clinical trial for the treatment of metastatic malignant melanoma using an approved breast-cancer drug.

The center has been studying the drug nab-paclitaxel, trade named Abraxane, for seven years.

The therapy was developed by biotechnology company Abraxis BioScience, which is conducting a worldwide, multicenter, multinational Phase 3 trial of Abraxane in metastatic melanoma, with Arizona Cancer Center physician scientist Dr. Evan Hersh as the principal investigator. 

For more informaiton: Cancer Center Studies Lead to New Trials for Malignant Melanoma Treatment